A Machine Learning Approach to Differentiate Between COVID-19 and Influenza Infection Using Synthetic Infection and Immune Response Data

Suzan Farhang-Sardroodi^{1, 2,*}, Mohammad Sajjad Ghaemi³, Morgan Craig⁶⁴, Hsu Kiang Ooi⁶³, and Jane M Heffernan^{61,2,*}

 ¹Modelling Infection and Immunity Lab, Mathematics Statistics, York University, Toronto, Canada
 ²Centre for Disease Modelling (CDM), Mathematics Statistics, York University, Toronto, Canada
 ³Digital Technologies Research Centre, National Research Council Canada, Toronto, ON, Canada
 ⁴Sainte-Justine University Hospital Research Centre and Department of Mathematics and Statistics, Université de Montréal, Montreal, Quebec, Canada
 ^{*}Corresponding Authors: suzanfa@yorku.ca, jmheffer@yorku.ca

January 28, 2022

13

12

2

3

4

5

Abstract

Data analysis is widely used to generate new insights into human disease mechanisms 14 and provide better treatment methods. In this work, we used the mechanistic models of viral 15 infection to generate synthetic data of influenza and COVID-19 patients. We then devel-16 oped and validated a supervised machine learning model that can distinguish between the 17 two infections. Influenza and COVID-19 are contagious respiratory illnesses that are caused 18 by different pathogenic viruses but appeared with similar initial presentations. While hav-19 ing the same primary signs COVID-19 can produce more severe symptoms, illnesses, and 20 higher mortality. The predictive model performance was externally evaluated by the ROC 21 AUC metric (area under the receiver operating characteristic curve) on 100 virtual patients 22 from each cohort and was able to achieve at least AUC=91% using our multiclass classifier. 23 The current investigation highlighted the ability of machine learning models to accurately 24 identify two different diseases based on major components of viral infection and immune 25 response. The model predicted a dominant role for viral load and productively infected 26 cells through the feature selection process. 27

Keywords: Biological Systems, Mechanistic Model, Infectious disease, Influenza (flu), COVID 19, Machine Learning, Classification, Logistic Regression, Regularization, Lasso, Ridge

30 1 Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza viruses cause 31 COVID-19 and influenza diseases, respectively, and mainly infect the upper and lower respi-32 ratory tract [1,2]. Both infections present some similar prime symptoms leading to a clinical 33 dilemma in diagnosing patients with the early infections [3–5]. However, COVID-19 tends to 34 cause worse decompensation due to its intensive transmission, and vascular effects which have 35 led to an unrivaled global crisis [6–9]. Moreover, as the striking COVID-19 outbreak contin-36 ues, the concurrence of epidemics can be impendent. Therefore, it is of interest to design data 37 analysis tools that can accurately differentiate between these two infections and help curb the 38 pandemics. 39

One way to rapidly classify patients as influenza or COVID-19 could be through machine 40 learning approaches. Preliminary investigation illustrated the potentials of machine-learning 41 models for accurately distinguishing between these two viral infections, using demographics, 42 body mass index, and vital signs in infected patients [9]. Herein, we used a simple ML-based 43 classification to identify the patients with influenza and SARS-CoV-2 using mathematically 44 based variables of the in-host infection dynamics and immune response. During the past decade, 45 virus-host mathematical modeling has become an increasingly powerful tool to study intracel-46 lular viral infection dynamics and the ensuing immune response. Dynamic mathematical mod-47 eling can deepen our understanding of virus spread within organs that amplify the development 48 of new antiviral drugs, and optimize treatment regimens. Importantly, these models can also 49 help to mitigate difficulties related to clinical data analyses, such as inconsistencies in data col-50 lection that can lead to biased trial results and significantly complicate comparative analytics. 51 For this purpose, we applied a basic mathematical model on the cellular scale (the so-called 52 target cell-limited model [10, 11]) fit two different sets of *in vivo* data, to create virtual patient 53 cohorts. Using our provided multiclass classifier, the patients were differentiated between the 54 two infections. We certainly hope that our work can be a guide for future applications validated 55 on the external clinical test set to help clinicians and front-line healthcare workers accurately 56 recognize the disease. With just some important in-host measurements clinicians may discern 57 the patients before a laboratory diagnosis. 58

This paper is organized as follows: In section 2, through subsection 2.1, we discuss the 59 In-host mathematical modelling of influenza and COVID-19 and parameter estimation. Via 60 subsection 2.2, we use the mechanistic model to generate synthetic patient data. In subsections 61 2.3 we study developing and evaluating a supervised machine learning method to discriminate 62 the patients with different infections. The Interpretability of the developed model is discussed 63 in subsection 2.4. The results of the prediction are presented in section 3 through subsection 64 3.1. Subsection 3.2 discusses the importance of the data features and determines the dominant 65 features. The paper concludes with a discussion in Section 4. 66




Figure 1: Schematic of viral infection. Each Target cell, T, is infected by a virus, V, with a constant rate β . During the eclipse period the productively infected cell, I_2 , is being produced by the first infected cell, I_1 , with a constant rate k. The Infected cell, I_2 , produces virus at rate p, IFNI at rate q and dies at rate δ per cell. IFNI hinders viral infection by converting target cells to a virus-resistant state with a constant rate ϕ and decays with rate d. Free virus particles that can be influenza or coronaviruses are cleared at per-capita rate c.

67 2 Method

68 2.1 Mechanistic models

We employed a target-cell limited model of viral dynamics using five differential equations that track susceptible target cells (T), infected cells in the eclipse phase (I_1) , productively infected cells (I_2) , virus (V), and interferon (F) in-host. Figure 1 presents a flow diagram of the model. The system of ordinary differential equations is as follows:

$$\frac{dT}{dt} = -\beta TV - \phi TF \tag{1a}$$

$$\frac{dI_1}{dt} = \beta T V - kI_1 \tag{1b}$$

$$\frac{dI_2}{dt} = kI_1 - \delta I_2 \tag{1c}$$

$$\frac{dV}{dt} = pI_2 - cV \tag{1d}$$

$$\frac{dF}{dt} = qI_2 - dF \tag{1e}$$

Briefly, virus particles V can infect susceptible target cells T to produce infected cells. This is

represented by the term βTV . Newly infected cells first enter the eclipse phase I_1 and become

⁷¹ productively infected cells I_2 when within-cell processes that program the cell to make new

virus particles are completed. The eclipse phase takes, on average, 1/k time units. Productively

infected cells produce new virus particles with a rate of p, and the virus particles are cleared 73 from the system with a rate of c. We assumed that productively infected target cells have a death 74 rate δ . Susceptible target cells can be protected from infection by Type I interferon (IFNI), 75 F. Type I interferons protect neighboring cells from infection and elicit an immune response 76 [12, 13]. They are central to combating different virus infections and are regularly measured 77 in clinical trials or infection studies in humans and animals [14]. We assumed that interferon 78 production is proportional to the number of productively infected cells, that interferon has a 79 natural decay rate d, and that interferon protects susceptible cells by removing them from the 80 susceptible target cells population, with a rate ϕF . This term was ignored in [10] for influenza 81 infection. The model described by Eq. 1 was used in [10] and [11] to examine the kinetics of 82 influenza A and SARS-CoV-2 viral dynamics, respectively. For the sake of simplicity, we have 83 ignored a half-day lag in IFNI response that was considered in [10]. 84

85 2.1.1 Parameter Estimation

Model parameters for influenza A infection were fit to data from an experimental H1N1 in-86 fluenza A/Hong Kong/123/77 infection for six patients [10] and for SARS-CoV-2 from thirteen 87 untreated patients infected with severe acute respiratory syndrome-coronavirus [11]. The geo-88 metric average parameter values along with their 95% confidence intervals and units are sum-89 marized in Table 1. We assumed that the initial number of target cells, T_0 , is equal to the total 90 number of target cells in the upper respiratory tract and set $T_0 = 4 \times 10^8$ cells. In [11] the 91 authors considered that the target cells distributed in a volume of 30 mL. Assuming that 1%92 of these cells expresses the angiotensin-converting enzyme 2 (ACE2) as a receptor for SARS-93 CoV-2, the target cell concentration, T_0 , was expressed as 1.33×10^5 cell/ml. Model variables 94 with initial values were estimated as in Table 2.

Table 1: Average values and confidence intervals, CI, for influenza A and SARS-CoV-2 withinhost viral infection model parameters. Confidence levels of 95% displays the degree of certainty that the parameter values for different samples, fall around the mean.

Influenza Model Parameters [10]									
$V_0 [95\% CI]$	R_0	β [95% CI]	k [95% CI]	$p \; [95\% CI]$	c [95% CI]	δ [95%CI]	q	d	ϕ
$TCID_{50}/ml^1$		$(TCID_{50}/ml)^{-1}d^{-1}$	d^{-1}	$(TCID_{50}/ml)d^{-1}$	d^{-1}	d^{-1}	d^{-1}	d^{-1}	$d^{-1}cell^{-1}$
0.075[7.6E - 4, 7.5]	21.5[10.1-46.1]	3.2E - 5[6E - 6, 1.7E - 4]	4[3, 5.2]	0.046[0.012, 0.17]	5.2[3.1 - 8.7]	5.2[3.2 - 8.6]	1	1.9 [12, 15, 16]	0
SD:3.5724	SD:17.15	SD:7.8124	SD:1.0486	SD:0.07527	SD:2.6677	SD:2.5724			
COVID-19 Model Parameters [11]									
V_0	$R_0 95\%[CI]$	β	k	$p \ 95\% [CI]$	c	δ 95%[CI]	q	d	ϕ
Copies/ml		$(Copies/ml)^{-1}d^{-1}$	d^{-1}	$(Copies/ml)d^{-1}$	d^{-1}	d^{-1}	d^{-1}	d^{-1}	$d^{-1}cell^{-1}$
0.1	8.6[1.9 - 17.6]	5.68E - 9	3	22.71[0 - 59.64]	10	0.6[0.22 - 0.97]	1	0.4	1.97E-6 [17]
	SD:12.9893			SD:49.3426		SD:0.62051			

 1 1 [*TCID*₅₀/*ml*] corresponds to 4000 [*Copies*/*ml*] [18]. 2 R_{0} is the basic reproduction number.

95

Variable	Definition	Initial Value	Unit
Т	Target cell	4E+8	Cell
I_1	Infected cell (eclipse phase)	0	Cell
I_2	Productively infected cell	0	Cell
V	Viral load (flu)	7.5E-2	$TCID_{50}/ml$
	(COVID-19)	0.1	Copies/ml
F	type I interferon (IFNI)	0	Interferon

Table 2: Model Variables with Initial values.

96 2.2 Generation of Virtual Patients

To generate a cohort of 100 virtual patients, we followed a technique similar to the one used 97 in [13]. Initial parameter sets representing individual virtual patients were drawn from normal 98 distributions with means fixed to the corresponding parameter value in Table 1 and standard 90 deviations derived from confidence interval measurements. Standard deviations were obtained 100 from standard errors, confidence intervals, and t statistics which measure the size of the differ-101 ence relative to the variation in the sample data. For each parameter value, the standard devi-102 ation was obtained by dividing the length of the confidence interval by standard errors width 103 $(2 \times t - value)$ and then multiplying by the square root of the sample size as follows 104

$$SD = \sqrt{N} \times SE = \sqrt{N} \times (upperlimit - lowerlimit)/(2 \times t - value)$$
 (2)

Standard errors must be of means calculated from within each parameter confidence interval. 106 The t - value for a 95% confidence interval from a sample size of N was then obtained in Mi-107 crosoft Excel using the tinv function (i.e. tinv(1-0.95, N-1)). From [10], the sample size for 108 the influenza cohort is 6 patients infected by H1N1 influenza A/Hong Kong/123/77 infection. 109 The COVID-19 cohort consisted of 13 untreated patients infected with severe acute Respiratory 110 syndrome-coronavirus [11]. Therefore, the t - value for influenza patients is 2.571 and for 111 COVID-10 patients is about 2.179. From normal distributions with standard deviations, σ , and 112 means, μ , as the original parameter values, we then generated normal distributions covering 113 values lying around each parameter value such that $|\mu \pm \sigma - \mu| < h$. Herein, the parameter 114 h is the user-defined value as a measure of data diversity. In the other words, the bigger the 115 parameter h, the more diverse the synthetic data. Accordingly, the external noise can affect the 116 data through the parameter h. The dynamics of 100 virtual patients from each cohort are shown 117 in Figure 2. The diversity of patient data is mainly reflected in various viral load levels to agree 118 with prior studies that different viral load is associated with the severity of diseases or different 119 factors such as age or sex of the patients [19]. 120

121 Consistency of the data

122 Generating data with time consistency for different cohorts of infections is of great importance.

¹²³ Data inconsistency can lead to loss of information or biased results. Since the influenza mech-

anistic model predicts faster clearance of influenza-infected cells than SARS-CoV-2 [11], the




Figure 2: Cohort Dynamics. One hundred virtual patients are generated with different features of Target cells, infected/productively infected cells, viral load, and the only immune factor type I interferon for Influenza (upper two rows) and COVID-19 (lower two rows). Each solid curve with a different color represents a patient. The insets are in log scale.




Figure 3: Consistency of the number of virtual data points during the time of infection. Dashed cross blue lines show eleven-time points of an influenza or COVID-19 patient.

infection period for influenza and COVID-19 patient dynamics are not the same, see Figure 125 2. Therefore we limited the consistency of flu/COVID-19 cohorts to have the same number of 126 data points during the infection time. Hereupon, as an example, we divided the main infection 127 period (i.e., [1-6] days for influenza patients and [10-20] days for COVID-19 patients) into 128 ten different sub-intervals with half-day length time steps for influenza patients and one and 129 half-day length time steps for COVID-19 patients (see Figure 3). Hence, despite having differ-130 ent infection periods and time steps with different lengths to report the new virtual data point. 131 the total number of data for the two different cohorts was the same. 132

In addition to the total infection period, we were also interested in studying the viral load dynamics in the early period of infection. The median incubation period for influenza A(B) virus is estimated to be 1.4(0.6) days, and for SARS-CoV-2 is around 5-6 days [20]. Therefore, we assumed the time interval [0.9, 1.3] days for influenza, and [5 - 6.5] days for COVID-19 cohorts, corresponding to $[10^2 - 10^4]Copies/ml$ viral load. Dividing each interval into three different sub-intervals to get the time steps with length one-sixth of a day for Influenza and half a day for COVID-19 patients, we had four consistent data points for each patient.

140 2.3 Predictive Model Development

To distinguish between patients who encounter COVID-19 from those who are exposed to influenza, we developed a predictive model based on some biological feature selections. Accordingly, we adopted Logistic regression with ℓ_1 -regularization, referred to Lasso (stands for least absolute shrinkage and selection operator) Regression, as an appropriate technical classification. Lasso regression is widely used for many supervised classification problems based on the concept of probability [21]. It can simplify the model complexity by removing irrelevant

features of the data set. Recently, this algorithm was used by Han et al. to find some addi tional novel immune features that accurately identified patients before the clinical diagnosis of
 preeclampsia [22].

Logistic regression, which is a special case of linear regression and used for binary classification, is defined by the following sigmoid function

152

160

164

$$h(X) = \frac{1}{1 + e^{-(\beta_0 + \beta X)}}$$
(3)

in which X is the $(n \times p)$ model feature matrix of n = 100 patients and p = 5 biological hallmarks. Defining the cost/objective (C) function of logistic regression in mean squared error format leads to a non-convexity that makes it difficult to optimally converge. Therefore, it is represented by the following equations

¹⁵⁷
$$C(h(X), Y) = \begin{cases} -log(h(X)), & \text{if } y = 1\\ -log(1 - h(X)), & \text{if } y = 0 \end{cases}$$
(4)

where Y is a binary response vector of outcome (CVOID-19 vs flu). Compressing the above two equations inside a single function, we have

$$J(X) = -\frac{1}{n} \sum_{i=1}^{n} \left[y_i log(h(x_i) + (1 - y_i) log(1 - h(x_i))) \right]$$
(5)

Replacing the sigmoid function from equation (3) and applying a penalty term equal to the absolute value of the magnitude of coefficients, we can reach the following objective function (after doing some mathematical simplifications) [22]

$$J(X) = -\left[\frac{1}{n}\sum_{i=1}^{n} y_i(\beta_0 + \beta^T x_i) - \log\left(1 + e^{\beta_0 + \beta^T x_i}\right)\right] + \alpha ||\beta||, \quad \alpha > 0$$
(6)

The penalty term which is called the ℓ_1 -regularization term is added to prevent data over-fitting. The model objective is to find a specific solution with a best-optimized cost function.

For model training and testing, we developed a \mathcal{K} -fold cross-validation strategy, which is 167 a re-sampling method to evaluate machine learning models on a limited data sample. The 168 procedure has a single parameter called \mathcal{K} which displays the number of groups that a given 169 data sample is to be split into. As such, the procedure is often called \mathcal{K} -fold cross-validation. 170 Therefore, our regression model is not tailored to a particular data set and is exposed to all 171 available samples of a given subject in the training set. This approach implies that the training 172 procedure was entirely blinded to the synthetic patient data sets, and ensures the presumed 173 independence from any intra-subject correlations that are required for Lasso classification. We 174 fixed the number of folds of the data as $\mathcal{K} = 5$. Running the analysis on each fold, the predicted 175 outcome will be the one with the least estimated prediction error. The regularization parameter 176 α is estimated by a cross-validation procedure. 177

178 2.3.1 Evaluating Model Performance

The discriminating ability of the developed model in predicting patients with influenza from 179 COVID-19 was evaluated using AUC (Area Under The Curve) ROC (Receiver Operating Char-180 acteristics) curve analysis. AUC - ROC curve is one of the most important evaluation metrics to 181 visualize the performance of multi-class classification problems. ROC represents a probability 182 curve of sensitivity (true positive rate= $\frac{TP}{TP+FN}$) against 1-specificity (false positive rate= $\frac{FP}{FP+TN}$) 183 and AUC is a performance measure of discrimination. In the other words, the AUC score is a 184 criterion that explains how well the model is capable of discerning different cohorts. Generally, 185 an AUC closer to 1 indicates a better overall diagnostic performance of influenza classes as 186 influenza or COVID-19 to COVID-19. 187

188 2.4 Model Interpretability

From [23, 24], "Interpretability" is the degree to which a human can understand the cause of a decision and consistently predict the model's result. The higher the interpretability of a machine learning model, the better understanding of why certain predictions have been made. Interpretable machine learning models are beneficial to extract the relevant knowledge from relationships either contained in data or learned by the model [25, 26].

Here, we looked at the regularization path which is a plot of all coefficients values against the values of α in- ℓ_1 penalization term, to see the behavior of the Lasso regression and interpret the prediction outcomes. The main purpose of Lasso regression is to classify groups of data by providing feature coefficients that can select the important features and maintain model regularization to avoid over-fitting the data. Therefore, the Lasso path can give us an idea of the feature's importance.

200 **3 Results**

3.1 Prediction of Influenza versus COVID-19 infection

In this study we developed a classifier in the Lasso framework to identify patients with either in-202 fluenza or COVID-19, based on four major entities of viral dynamics, $\{T(t), I_1(t), I_2(t), V(t)\}$, 203 and one main factor of host immune response, type I interferon (F(t)), as the entry data fea-204 tures. The model was trained on data from one hundred virtual patient-level data in each infec-205 tion cohort without noise, and it was externally validated on testing set with demographic noise 206 (reflected in diverse viral load levels). Results in Figures 4, 5 and 6 reflect the Lasso predictions 207 using the entire infection period (see Section 2.2). In Figures 4 and 5, two-dimensional scatter 208 plots are used to compare ground truth to regression predicted values based on all model fea-209 tures. The hue spectrum from light to dark illustrates the probability of being in the influenza 210 (blue) or COVID-19 (red) group. In the other words, the darker the colors, the better the pre-211 diction. Considering three attributes in the data, the predicted outcomes are improved. This 212

is shown in three-dimensional scatter plots in Figure 6 of the ground truth and regression predicted values. ROC AUC=95% indicates a satisfactory performance of the model to distinguish

²¹⁵ between COVID-19 and influenza patients, see figure 7 for more details.

Early days of infection

We examined the model prediction for the data generated at the early days of infection after 217 the incubation period. The results are shown in Figure 8 based on the model features. From 218 the figure, we can see that there are some mispredictions, for small values of $I_1(t), I_2(t), V(t)$, 219 and F(t), especially when $I_2(t)$ is plotted as a function of $I_1(t)$ or V(t) is plotted in terms of 220 $I_2(t)$. In the other words, for this range of values, the influenza patients were misdiagnosed with 221 COVID-19. In an attempt to find the reason, we compared correlations between the different 222 variables in our model – see Figure 9). Here, we see small regions of overlap between influenza 223 and COVID-19 models. Accordingly, the compatibility of the results between the two infections 224 may lead to some overlaps in the model predictions. However, the ability of the model in the 225 prediction of infections when the patients were monitored by V(t)/F(t) as a function of $I_1(t)$, 226 panels (b) and (c), or F(t) in terms of $I_2(t)/V(t)$, panels (e) and (f), can be satisfactory, and 227 thus can serve as benchmarks for clinical diagnosis. The model had a ROC AUC of 91% on the 228 external validation data set for early infection – see Figure 7. 229

3.2 Significance of the features

To investigate the importance of various data features we created our ℓ_1 -regularization path, 231 which was the best way to see the behavior of the Lasso regression. The regularization path 232 is a plot of all coefficient values in terms of the regularization parameter. Figure 10 illustrates 233 the selection path of each feature with its corresponding coefficient in terms of the logarithm 234 of the regularization parameter α . For each value of α , the path method on the Lasso object 235 returns the coefficients that solve the logistic regression problem with that parameter value. The 236 optimal value of $-\log(\alpha)$ was estimated at around 3.25 for the test set distributed over the entire 237 infection course, and 3.04 when the early days of infection were studied. The results suggested 238 a higher coefficient value for viral load V(t) and productively infected cells $I_2(t)$ compared to 239 the other features. 240

4 Discussion

This study presents a machine learning model to effectively classify influenza and COVID-19 virtual patients using in-host patient data. Our model employed a Lasso regression classifier trained to identify between two hundred patients, highlighted by a ROC AUC of 95%. Using the existing within-host models, We generated synthetic data with five in-host measurements including target cells, eclipse phase, and productively infected cells, viral load, and type I IFN. Analyzing the feature importance revealed that the viral load and the productively infected cells




Figure 4: Two-dimensional scatter plots of ground truth and regression predicted values based on model features. Classification of the data was done for: I_2 versus I_1 in panels (a), T vs. I_1 in panels (b), V vs. I_1 in panels (c), F vs. I_1 in panels (d), T vs. I_2 in panels (e), V versus I_2 in panels (f), and F versus I_2 in panel (g). Color denotes the patient probability of being in the influenza (blue color scheme) or COVID-19 (red color scheme) cohorts. Data points, corresponding to each model feature, are rescaled by dividing by their standard deviations.




Figure 5: Two-dimensional scatter plots of the ground truth and regression predicted values for three model features T, V, F. Classification of the data was done based on: T versus V in panels (a), T versus F in panels (b), and F versus V in panels (c). Color denotes the patient probability of being in the influenza (blue color scheme) or COVID-19 (Red color scheme) cohorts.




Figure 6: Three-dimensional scatter plots of the ground truth and regression predicted values based on all model features. Classification is based on I_1, I_2, T in panels (a), I_1, I_2, V in panels (b), I_1, I_2, F in panels (c), T, V, F in panels (d), I_1, T, V in panels (e), I_2, T, V in panels (f), I_1, T, F in panels (g), I_2, T, F in panels (h), I_1, F, V in panels (i), and I_2, F, V in panels (j). Shades of blue (red) indicate influenza (COVID-19) group patients. Data points are dimensionless by dividing by the corresponding standard deviations.




Figure 7: Receiver Operating Characteristic curve (ROC) of influenza vs COVID-19 patients. Area under the ROC curve indicates the predictive performance of the model between COVID-19 and influenza encounters on the external validation test during the main infection (blue curve) and early days (orange curve). The black dashed line in the diagonal has a ROC AUC of 0.5.

are the most important components to determine if a patient is infected by influenza or SARS CoV-2.

While our machine learning model was built on the synthetic data distributed during the 250 main infection period, it ascertained a good performance (ROC AUC = 91%) even for the early 251 days, once after the incubation period. However, there are some exceptions for the small values 252 of in-host features where the influenza patients are misdiagnosed by COVID-19 for the early 253 days of infection. The reason was explained by the fact that during the early days of the in-254 fection, influenza and COVID-19 patients have comparable in-host measurements that lead to 255 some errors in discriminating the patients. This is interpreted as a limitation of our model and 256 can be a future extension of developing dynamic models which take more immune entities into 257 account and end in a better classifier. 258

Our model was trained and successfully evaluated on synthetic data. The model, however, 259 could be applied to animal or human clinical data. This could be useful, for example, if a clinical 260 trial is complicated by the existence of an infectious disease with similar infection character-261 istics. The model could be applied as a low-cost classification system that would not require 262 expensive virus typing procedures and could rely solely on viral load and interferon measure-263 ments. We note that studies like [9] that focus analysis on demographic and observational data 264 can be cheaper to conduct, but these data can also be subject to inconsistencies and bias, af-265 fecting classification outcomes. In a future study, we will expand our analysis to a model of 266 in-host measurements and observational data to determine if specific combinations of in-host 267 and observational data that best classify influenza and COVID-19 infections differ. 268




Figure 8: Early days of infection. Two-dimensional scatter plots of the ground truth and regression predicted values based on model features are shown. Classification is based on I_1 , I_2 in panels (a), I_1 , V in panels (b), I_1 , F in panels (c), I_2 , V in panels (d), I_2 , F in panels (e), and V, F in panels (f). Shades of blue (red) indicate influenza (COVID-19) group patients. Data points are dimensionless by dividing by the corresponding standard deviations.




Figure 9: Comparison of in-host measurements, $\{T, I_1, I_2, V, F\}$, between influenza and COVID-19 virtual patients where plotted as a function of each other. Blue(red) solid lines represent the ratio of the features for one hundred influenza (COVID-19) patients. Data points are divided by the corresponding standard deviations for each feature.




Figure 10: Lasso coefficients of five sample features, $\{T, I_1, I_2, V, F\}$, as a function of the logarithm of regularization parameter, $-\log \alpha$. Each colored line represents the value taken by a different coefficient in the optimization objective for Lasso. The black dashed line indicates the selected regularization parameter with the value of $-\log(\alpha) \approx 3.25$. This number was ≈ 3.04 with the same Lasso Paths when the early days of the infection period were considered.

Our machine learning model was developed in the Lasso framework. Ridge regression could also be employed, and require only small changes to our method to include this. We find that the model demonstrated a satisfactory performance by using a Ridge regression classifier – (ROC AUC= 95%) for the main infection period, and (ROC AUC= 89%) for the early days of infection.

274 **References**

- [1] Kanta Subbarao and Siddhartha Mahanty. Respiratory virus infections: understanding covid-19. Immunity, 52(6):905–909, 2020.
- [2] Laura D Manzanares-Meza and Oscar Medina-Contreras. Sars-cov-2 and influenza: a
 comparative overview and treatment implications. <u>Boletín médico del Hospital Infantil de</u>
 México, 77(5):262–273, 2020.
- [3] Shuhei Azekawa, Ho Namkoong, Keiko Mitamura, Yoshihiro Kawaoka, and Fumitake
 Saito. Co-infection with sars-cov-2 and influenza a virus. IDCases, 20:e00775, 2020.
- [4] Pavan K Bhatraju, Bijan J Ghassemieh, Michelle Nichols, Richard Kim, Keith R Jerome,
 Arun K Nalla, Alexander L Greninger, Sudhakar Pipavath, Mark M Wurfel, Laura Evans,
 et al. Covid-19 in critically ill patients in the seattle region—case series. <u>New England</u>
 Journal of Medicine, 382(21):2012–2022, 2020.
- [5] Hossein Khorramdelazad, Mohammad Hossein Kazemi, Alireza Najafi, Maryam Keykhaee, Reza Zolfaghari Emameh, and Reza Falak. Immunopathological similar ities between covid-19 and influenza: Investigating the consequences of co-infection. Microbial pathogenesis, 152:104554, 2021.
- [6] Maximilian Ackermann, Stijn E Verleden, Mark Kuehnel, Axel Haverich, Tobias Welte,
 Florian Laenger, Arno Vanstapel, Christopher Werlein, Helge Stark, Alexandar Tzankov,
 et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in covid-19. <u>New</u>
 England Journal of Medicine, 383(2):120–128, 2020.
- [7] Qun Li, Xuhua Guan, Peng Wu, Xiaoye Wang, Lei Zhou, Yeqing Tong, Ruiqi Ren, Kathy SM Leung, Eric HY Lau, Jessica Y Wong, et al. Early transmission dynamics in wuhan, china, of novel coronavirus–infected pneumonia. <u>New England journal of</u> <u>medicine</u>, 2020.
- [8] Na Zhu, Dingyu Zhang, Wenling Wang, Xingwang Li, Bo Yang, Jingdong Song, Xiang
 Zhao, Baoying Huang, Weifeng Shi, Roujian Lu, et al. A novel coronavirus from patients
 with pneumonia in china, 2019. New England journal of medicine, 2020.

[9] Naveena Yanamala, Nanda H Krishna, Quincy A Hathaway, Aditya Radhakrishnan,
 Srinidhi Sunkara, Heenaben Patel, Peter Farjo, Brijesh Patel, and Partho P Sengupta. A vi tal sign-based prediction algorithm for differentiating covid-19 versus seasonal influenza
 in hospitalized patients. NPJ digital medicine, 4(1):1–10, 2021.

[10] Prasith Baccam, Catherine Beauchemin, Catherine A Macken, Frederick G Hayden, and
 Alan S Perelson. Kinetics of influenza a virus infection in humans. Journal of virology,
 80(15):7590–7599, 2006.

[11] Antonio Gonçalves, Julie Bertrand, Ruian Ke, Emmanuelle Comets, Xavier De Lambal lerie, Denis Malvy, Andrés Pizzorno, Olivier Terrier, Manuel Rosa Calatrava, France Men tré, et al. Timing of antiviral treatment initiation is critical to reduce sars-cov-2 viral load.
 CPT: pharmacometrics & systems pharmacology, 9(9):509–514, 2020.

[12] Pengxing Cao, Ada WC Yan, Jane M Heffernan, Stephen Petrie, Robert G Moss, Louise A
Carolan, Teagan A Guarnaccia, Anne Kelso, Ian G Barr, Jodie McVernon, et al. Innate
immunity and the inter-exposure interval determine the dynamics of secondary influenza
virus infection and explain observed viral hierarchies. <u>PLoS computational biology</u>,
11(8):e1004334, 2015.

[13] Adrianne L Jenner, Rosemary A Aogo, Sofia Alfonso, Vivienne Crowe, Xiaoyan Deng,
 Amanda P Smith, Penelope A Morel, Courtney L Davis, Amber M Smith, and Morgan
 Craig. Covid-19 virtual patient cohort suggests immune mechanisms driving disease out comes. PLoS pathogens, 17(7):e1009753, 2021.

[14] Finlay McNab, Katrin Mayer-Barber, Alan Sher, Andreas Wack, and Anne O'garra. Type
 i interferons in infectious disease. <u>Nature Reviews Immunology</u>, 15(2):87–103, 2015.

[15] Frederick G Hayden, R Fritz, Monica C Lobo, W Alvord, Warren Strober, Stephen E
 Straus, et al. Local and systemic cytokine responses during experimental human influenza
 a virus infection. relation to symptom formation and host defense. <u>The Journal of clinical</u>
 investigation, 101(3):643–649, 1998.

[16] Kasia A Pawelek, Giao T Huynh, Michelle Quinlivan, Ann Cullinane, Libin Rong, and
 Alan S Perelson. Modeling within-host dynamics of influenza virus infection including
 immune responses. <u>PLoS computational biology</u>, 8(6):e1002588, 2012.

[17] Naveen K Vaidya, Angelica Bloomquist, and Alan S Perelson. Modeling within-host dynamics of sars-cov-2 infection: A case study in ferrets. <u>Viruses</u>, 13(8):1635, 2021.

[18] Licia Bordi, Giuseppe Sberna, Eleonora Lalle, Pierluca Piselli, Francesca Colavita,
Emanuele Nicastri, Andrea Antinori, Evangelo Boumis, Nicola Petrosillo, Luisa Marchioni, et al. Frequency and duration of sars-cov-2 shedding in oral fluid samples assessed
by a modified commercial rapid molecular assay. Viruses, 12(10):1184, 2020.

- [19] Waleed H Mahallawi, Ali Dakhilallah Alsamiri, Alaa Faisal Dabbour, Hamdah Alsaeedi,
 and Abdulmohsen H Al-Zalabani. Association of viral load in sars-cov-2 patients with
 age and gender. Frontiers in Medicine, 8:39, 2021.
- [20] Keisuke Ejima, Kwang Su Kim, Christina Ludema, Ana I Bento, Shoya Iwanami, Yasuhisa Fujita, Hirofumi Ohashi, Yoshiki Koizumi, Koichi Watashi, Kazuyuki Aihara,
 et al. Estimation of the incubation period of covid-19 using viral load data. <u>Epidemics</u>,
 35:100454, 2021.
- [21] Robert Tibshirani. Regression shrinkage and selection via the lasso. Journal of the Royal
 Statistical Society: Series B (Methodological), 58(1):267–288, 1996.
- [22] Xiaoyuan Han, Mohammad S Ghaemi, Kazuo Ando, Laura S Peterson, Edward A
 Ganio, Amy S Tsai, Dyani K Gaudilliere, Ina A Stelzer, Jakob Einhaus, Basile Bertrand,
 et al. Differential dynamics of the maternal immune system in healthy pregnancy and
 preeclampsia. Frontiers in immunology, 10:1305, 2019.
- [23] Tim Miller. Explanation in artificial intelligence: Insights from the social sciences.
 Artificial intelligence, 267:1–38, 2019.
- [24] Been Kim, Rajiv Khanna, and Oluwasanmi O Koyejo. Examples are not enough, learn
 to criticize! criticism for interpretability. Advances in neural information processing
 systems, 29, 2016.
- W James Murdoch, Chandan Singh, Karl Kumbier, Reza Abbasi-Asl, and Bin Yu. Definitions, methods, and applications in interpretable machine learning. <u>Proceedings of the</u> National Academy of Sciences, 116(44):22071–22080, 2019.
- ³⁵⁷ [26] Christoph Molnar. Interpretable machine learning. Lulu. com, 2020.